This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sitthisomwong, P. Articles by Siegel, A. Search for Related Content PubMed PubMed Citation Articles by Sitthisomwong, P. Articles by Siegel, A. Social Bookmarking                         What's this?

The Effect of a Cholecystokinin Agonist on Masseter Muscle Activity in the Cat

Division of Occlusion, Department of Prosthodontics, Faculty of Dentistry, Mahidol University, Bangkok, Thailand

S. Weiner

departments of Oral Biology, Prosthodontics and Biomaterials, New Jersey Dental School, Room D830, 110 Bergen Street, Newark, NJ 07103, USA

L. Levin

Pre-doctoral student, NJ Dental School

S. Reisman

Department of Electrical Engineering, New Jersey Institute of Engineering

A. Siegel

Department of Neurosciences, New Jersey Medical School

The CCKB agonist, pentagastrin, has been shown to induce anxiety in human subjects. Similarly, in the cat model, pentagastrin facilitates the expression of hypothalamically activated emotional behavior. Because hypothalamically mediated emotional behavior is also accompanied by increased EMG activity in the jaw muscles, these experiments were designed to examine the combined effects of administration of pentagastrin with activation of hypothalamically mediated emotional behavior upon jaw muscle EMG activity. Electrodes were carefully lowered through previously placed guide tubes overlying the hypothalamus until a behavioral site was identified. Following the establishment of a stable threshold current for eliciting an emotional behavioral response, the skin overlying the ipsilateral masseter muscle was shaved and cleaned with alcohol, and surface electrodes were attached. The EMG was recorded, amplified, digitized, and stored in a microcomputer for analysis. Mean power frequencies (MPF) and latencies for behavior were calculated for baseline prior to infusion of all drugs. Following this, the effects of intravenous administration of pentagastrin and the CCKB antagonist LY288513 on the MPF were determined. The infusion of the CCKB agonist, pentagastrin (0.77, 1.92, and 3.84 µg/kg), decreased MPF in a time-related manner. The effects of pentagastrin 1.92 µg/kg were blocked by the CCKB antagonist, LY288513 (6.54 µg/kg). In addition, the infusion of LY288513 alone increased MPF. These results are surprising in that pentagastrin's anxiogenic properties would appear to make it likely to facilitate motor activity, not suppress it.

Key Words: cholecystokinin agonist • masseter muscle • electromyography • defensive rage.

Journal of Dental Research, Vol. 79, No. 10, 1823-1828 (2000)
DOI: 10.1177/00220345000790101501


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?